ライフサイエンスコーパス: hematopoietic cell

1 lture-initiating cell assay cells (primitive hematopoietic cells).

2 of induced RASGRP1 overexpression in primary hematopoietic cells.

3 s during short-term or long-term tracking of hematopoietic cells.

4 uled out a requirement for PHD2 signaling in hematopoietic cells.

5 ing and bone marrow (BM) retention of normal hematopoietic cells.

6 nine nucleotide exchange factor expressed in hematopoietic cells.

7 elic inactivation of the respective genes in hematopoietic cells.

8 entiation state in both normal and malignant hematopoietic cells.

9 ysis of human-specific pathogens that infect hematopoietic cells.

10 IS mice, had minimal effects on normal human hematopoietic cells.

11 was not attributable to lymphocytes or other hematopoietic cells.

12 ecial type of proteasome mainly expressed in hematopoietic cells.

13 was not induced by transfer of Ttc7-mutated hematopoietic cells.

14 plants are repopulated with autologous human hematopoietic cells.

15 is of DB818-treated murine Hoxa9-transformed hematopoietic cells.

16 d Nom1, are essential for the maintenance of hematopoietic cells.

17 n of leukemic cells without impacting normal hematopoietic cells.

18 re mainly caused by enhanced accumulation of hematopoietic cells.

19 esis pathway expression compared with normal hematopoietic cells.

20 minant of HCMV tropism for select subsets of hematopoietic cells.

21 mage, is compromised in Foxo3(-/-) primitive hematopoietic cells.

22 ase Atad3a hyperactivated mitophagy in mouse hematopoietic cells.

23 ated mice lacking LIFR in either CD11c(+) or hematopoietic cells.

24 diation preconditioning to ablate endogenous hematopoietic cells.

25 liferation, survival, and differentiation of hematopoietic cells.

26 to the development and lineage commitment of hematopoietic cells.

27 provides a distinct competitive advantage to hematopoietic cells.

28 In these models, Nf1 haploinsufficiency in hematopoietic cells accelerated tumor onset and increase

29 nscription factor predominantly expressed in hematopoietic cells, acts as an essential regulator of h

30 to SP and NK-A to protect the most primitive hematopoietic cell and also to maintain immune/hematopoi

31 safely induces immune tolerance to combined hematopoietic cell and organ allografts in humans.

32 current knowledge on cortactin expression in hematopoietic cells and discusses the functional implica

33 cells cause an expanded population of mutant hematopoietic cells and drive an aberrant inflammatory s

34 ggering apoptosis in specific cells, such as hematopoietic cells and endothelium.

35 -/-) mice have decreased MHC-I expression on hematopoietic cells and fewer CD8(+) T cells prior to in

36 a ubiquitous pathogen that latently infects hematopoietic cells and has the ability to reactivate wh

37 s (PI3Ks) gamma and delta are key enzymes in hematopoietic cells and have been seen as high-value tar

38 ppressor, which regulates the homeostasis of hematopoietic cells and immune responses.

39 py on PI-PLCbeta1 inositide signaling, using hematopoietic cells and MDS samples.

40 T cells was dependent on TLR9 expression on hematopoietic cells and partially dependent on receptor

41 tibodies inhibited leukemic, but not normal, hematopoietic cells and synergized with other antileukem

42 netic screen, comparing normal primary mouse hematopoietic cells and their malignant counterparts in

43 Chimeric mice deficient for Notch3 in hematopoietic cells and/or resident tissue cells were ge

44 As Gdf11 is expressed by mature hematopoietic cells, and erythroid precursor cell expres

45 esis (enterocytes, hepatocytes, macrophages, hematopoietic cells, and in the case of pregnancy, place

46 e is expressed in many cell types, including hematopoietic cells, and is a member of the Tec kinase f

47 rate of protein synthesis relative to other hematopoietic cells, and it can be easily adapted to qua

48 ersistence of higher VCN in the repopulating hematopoietic cells are associated with better outcome.

49 We show that metabolic alterations in hematopoietic cells are fundamental to the pathogenesis

50 marrow transplantation experiments identify hematopoietic cells as the predominant source of plasma

51 numbers and impaired B cell development in a hematopoietic cell-autonomous manner.

52 has been until recently considered absent in hematopoietic cells because these cells express the cort

53 that Grasp55 plays a role in Myc-transformed hematopoietic cells but not in normal hematopoietic cell

54 ion in the host and to a lesser extent donor hematopoietic cells by overexpressing the RA-catabolizin

55 , rather than a local role for Tmprss6-/- in hematopoietic cells, contributes to the MEP lineage comm

56 Nkx2.3(-/-) hematopoietic cells could not rescue wild-type mice from

57 These results establish that IUHCT of hematopoietic cells decorated with GSK3 inhibitor-loaded

58 Taken together, these results reveal that hematopoietic cell-derived Gdf11 is largely dispensable

59 In addition, although hematopoietic cell-derived Gdf11 may contribute to the p

60 ess functions of the Id3 and/or Tet2 gene in hematopoietic cell development and clonal hematopoiesis.

61 e the causal role of heterochromatin loss in hematopoietic cell development.

62 tt lymphoma, including genes associated with hematopoietic cell differentiation (FLI1, BCL11A) or B-c

63 dies identify a pathogenic role for Hsp70 in hematopoietic cells during allergic airway inflammation;

64 We identified 28 subsets of non-hematopoietic cells during homeostasis, 14 of which expr

65 ost HSCs, enabling rapid and efficient donor hematopoietic cell engraftment.

66 y limits the activation and proliferation of hematopoietic cells, enhances the gammaherpesvirus-drive

67 ted biological functions and pathways during hematopoietic cell expansion and development.

68 which is unresponsive to transplant due to a hematopoietic cell-extrinsic mechanism.

69 ritical regulator of inflammation controlled hematopoietic cell fate decisions of HSCs.

70 neurotrophins have the potential to regulate hematopoietic cell fate decisions.

71 ing a role for O-GlcNAcylation in regulating hematopoietic cell fate.

72 ught to examine whether macrophages or other hematopoietic cells found in the embryo prior to HSC gen

73 Transplantation of hematopoietic cells from a healthy individual (allogenei

74 e substantially greater in baboons receiving hematopoietic cells from a pig expressing high levels of

75 We hypothesized that hematopoietic cells from a restricted lineage would be m

76 y chimeras that lacked GILT in both TECs and hematopoietic cells had a high conventional T/Treg cell

77 oietic and nonhematopoietic cells, Map3k8 in hematopoietic cells has a more dominant role.

78 ntinuous quantitative single-cell imaging of hematopoietic cells has been used to solve decades-long

79 However, RAS activation in hematopoietic cells has immunologic effects that diverge

80 raftment of normal and diseased human immune/hematopoietic cells has made in vivo functional characte

81 ymphomas (EBV-PTLD) after transplantation of hematopoietic cell (HCT) or solid organ (SOT) but is una

82 General Hospital, we pioneered simultaneous hematopoietic cell (HCT)/kidney transplantation from HLA

83 the maintenance and expansion of multipotent hematopoietic cells, i.e. hematopoietic stem cells (HSCs

84 acted with nascent and emerging intra-aortic hematopoietic cells (IAHCs).

85 itional deletion of Bmal1 in endothelium and hematopoietic cells in murine models of microvascular an

86 Total body irradiation (TBI) damages hematopoietic cells in the bone marrow and thymus; howev

87 ive regulator of the CXCR4 retention axis of hematopoietic cells in the bone marrow.

88 Progenitors of the first hematopoietic cells in the mouse arise in the early embr

89 By transplantation of lentiviral-transduced hematopoietic cells in the Mpl-deficient mouse model, we

90 fferentially interacts with murine and human hematopoietic cells in these mouse models and how these

91 d infer cellular dynamics of differentiating hematopoietic cells in vitro and in vivo.

92 formed hematopoietic cells but not in normal hematopoietic cells in vivo.

93 nant state in normally differentiating human hematopoietic cells in which MYC expression has been der

94 Here we show that in hematopoietic cells, including multiple myeloma (MM), ly

95 On Mx1-Cre activation in hematopoietic cells induced by poly (I:C) injection, all

96 rrent Tet2 loss and Nras(G12D) expression in hematopoietic cells induced myeloid transformation, with

97 focused on the molecular mechanisms by which hematopoietic cells initiate and maintain innate and ada

98 Thus, activation of NLRP3 in hematopoietic cells initiates IL-1beta-driven paracrine

99 Our data suggest a hematopoietic cell-intrinsic role of Lsh in B cell devel

100 analyses suggest that CD70 expressed by host hematopoietic cells is involved in the control of allore

101 he hypomethylation phenotype of Dnmt3a (-/-) hematopoietic cells is reversible, we developed an induc

102 RAGE expressed on stromal cells, rather than hematopoietic cells, is critical to induction of asthma/

103 nt activation of an Src family kinase (SFK), hematopoietic cell kinase (HCK), specifically in DCs in

104 gene programs underlying the development of hematopoietic cell lineages.

105 he effects of anti-cancer agents on multiple hematopoietic cell lineages.

106 the different DDR outcomes utilized by human hematopoietic cell lines and primary human HSPC.

107 and compared the replication of the virus in hematopoietic cell lines with that of FeLV-A 61E by meas

108 ression pattern of metabolic pathways of two hematopoietic cell lines, we find that the relative posi

109 cytotoxic agents in C57BL/6 mice in vivo and hematopoietic cell lines.

110 erotic lesion formation, which suggests that hematopoietic cells mediate the proatherosclerotic pheno

111 DOCK8, a guanine exchange factor involved in hematopoietic cell migration, lead to immunodeficiency a

112 We used both an experimental hematopoietic cell model of latency and cells from natur

113 Gene set enrichment analysis predicts hematopoietic cell number and cell infiltration are modu

114 Here we show that in hematopoietic cells, Nup98 binds predominantly to transc

115 Hematopoietic cells of the marrow are regionally decimat

116 se variants confers a selective advantage to hematopoietic cells on DNA damage.

117 ypes could be complemented by wild-type (WT) hematopoietic cells or administration of exosomes produc

118 immune cells, such as natural killer cells, hematopoietic cells or induced pluripotent stem cells, t

119 Hematopoietic-cell or solid-organ transplant recipients

120 maribavir dose-blinded trial, recipients of hematopoietic-cell or solid-organ transplants (>=18 year

121 for clearing CMV viremia among recipients of hematopoietic-cell or solid-organ transplants.

122 fluorescence microscopy were used to analyze hematopoietic cell population dynamics and the cellular

123 Immune pathway heterogeneity of hematopoietic cell populations in breast tumors correspo

124 onstrate that ectopic expression of Snai1 in hematopoietic cells predisposes mice to AML development.

125 n GPS are known to be synthesized outside of hematopoietic cells, predominantly in the liver.

126 at Fbxl8 antagonizes cell cycle progression, hematopoietic cell proliferation, and oncogene-induced t

127 ecular bone and collagen fibers that replace hematopoietic cells, resulting in abnormal bone marrow f

128 ted by RIPK1, RIPK3, and MLKL kinases but in hematopoietic cells RIPK1 has anti-inflammatory roles an

129 single-cell gene-activity profiles of human hematopoietic cells showed that LTA induces genes restri

130 ics by dedicator of cytokinesis 2 (DOCK2), a hematopoietic cell-specific actin effector protein, has

131 Hematopoietic cell-specific deletion of PTN suppressed C

132 etic system, we generated a mouse model with hematopoietic cell-specific knockout of Hopx (Hopx(-/-))

133 se these cells express the cortactin homolog hematopoietic cell-specific lyn substrate-1.

134 to blood cell phenotypes, delineate relevant hematopoietic cell states influenced by regulatory genet

135 ctional expression of cortactin in different hematopoietic cells, such as macrophages, dendritic cell

136 the importance of cytokine-directed cues for hematopoietic cell survival and differentiation, the imp

137 stem cells, but not in normal CD34(+)CD38(-) hematopoietic cells, T cells, or vital tissues.

138 Clonal expansions of mutated hematopoietic cells, termed clonal hematopoiesis, are co

139 ts a specific, nonredundant role for RAC2 in hematopoietic cells that discriminates RAC2 from the rel

140 ed a conditioning regimen, infusion of donor hematopoietic cells, then immunosuppressive drugs and an

141 particles conjugated to the surface of donor hematopoietic cells to enhance their proliferation kinet

142 a pooled loss-of-function screen in primary hematopoietic cells to interrogate 389 candidate genes c

143 on factor in the terminal differentiation of hematopoietic cells to the monocytes has been well estab

144 tal stage in which HCMV infects, HCMV drives hematopoietic cells towards a weaker immune-responsive m

145 HE cells undergo an endothelial to hematopoietic cell transition, giving rise to HSPCs that

146 a significant complication facing allogeneic hematopoietic cell transplant (allo-HCT) recipients, as

147 use of morbidity and mortality in allogeneic hematopoietic cell transplant (allo-HCT) recipients.

148 tic cell transplant (autoHCT) and allogeneic hematopoietic cell transplant (alloHCT).

149 yeloid leukemia (AML), as well as autologous hematopoietic cell transplant (autoHCT) and allogeneic h

150 Hematopoietic cell transplant (HCT) and solid organ tran

151 eiving intensive chemotherapy and the use of hematopoietic cell transplant (HCT) for specific high-ri

152 Only hematopoietic cell transplant (HCT) has been shown to ha

153 ary graft-versus-host disease (cpGVHD) after hematopoietic cell transplant (HCT) manifests as progres

154 Hematopoietic cell transplant (HCT) recipients are frequ

155 rgies among solid organ transplant (SOT) and hematopoietic cell transplant (HCT) recipients are limit

156 guidelines recommend vaccinating allogeneic hematopoietic cell transplant (HCT) recipients at 3 mont

157 guidelines recommend vaccinating allogeneic hematopoietic cell transplant (HCT) recipients at 3 mont

158 and preventing disseminated viral disease in hematopoietic cell transplant (HCT) recipients but does

159 Cytomegalovirus (CMV) infections in hematopoietic cell transplant (HCT) recipients cause sub

160 solized RBV, we aimed to compare outcomes of hematopoietic cell transplant (HCT) recipients treated w

161 sample types, including (i) whole blood from hematopoietic cell transplant (HCT) recipients with and

162 associated with substantial morbidity among hematopoietic cell transplant (HCT) recipients, but the

163 sk patients with hematologic malignancies or hematopoietic cell transplant (HCT) recipients.

164 rding the impact of human bocavirus (BoV) in hematopoietic cell transplant (HCT) recipients.

165 is associated with significant mortality in hematopoietic cell transplant (HCT) recipients.

166 V) infection causes significant morbidity in hematopoietic cell transplant (HCT) recipients.

167 Seq) test for diagnosing pulmonary IMI after hematopoietic cell transplant (HCT).

168 h mortality in ex vivo T-cell depleted (TCD) hematopoietic cell transplant (HCT).

169 elapse mortality (NRM) after unrelated donor hematopoietic cell transplant (HCT).

170 s of allogeneic (Allo) and autologous (Auto) hematopoietic cell transplant and CD19-directed chimeric

171 3 consecutive young males with cALD prior to hematopoietic cell transplant and its association with m

172 tiocytosis, congenital immunodeficiency, and hematopoietic cell transplant are independently associat

173 Hematopoietic cell transplant candidates and recipients

174 l infection within 100 days after allogeneic hematopoietic cell transplant increases risk of pulmonar

175 st disease (GVHD) occurring after allogeneic hematopoietic cell transplant is an allo-reactive T cell

176 med a retrospective review of 738 allogeneic hematopoietic cell transplant patients enrolled from 200

177 se of infectious complications in allogeneic hematopoietic cell transplant recipients (alloHCT).

178 It is widely used in hematopoietic cell transplant recipients but is infreque

179 ains a major complication in solid organ and hematopoietic cell transplant recipients.

180 totoxic chemotherapy regimens and allogeneic hematopoietic cell transplant to achieve the best long-t

181 y immunocompromised diagnosis and history of hematopoietic cell transplant, and among survivors immun

182 Among patients without hematopoietic cell transplant, congenital immunodeficien

183 Among patients with prior hematopoietic cell transplant, liquid malignancy (adjust

184 of morbidity and mortality after allogeneic hematopoietic cell transplant.

185 lood specimens from recipients of allogeneic hematopoietic cell transplant.

186 Autologous hematopoietic cell transplantation (AHCT) consolidation

187 e-cycle melphalan 200 mg/m(2) and autologous hematopoietic cell transplantation (AHCT) followed by le

188 Allogeneic hematopoietic cell transplantation (allo-HCT) can cure t

189 Although allogeneic hematopoietic cell transplantation (allo-HCT) is current

190 Allogeneic hematopoietic cell transplantation (allo-HCT) is indicat

191 into the intestinal mucosa after allogeneic hematopoietic cell transplantation (allo-HCT) triggers n

192 cells from a healthy individual (allogeneic hematopoietic cell transplantation (allo-HCT)) demonstra

193 In patients who received allogeneic hematopoietic cell transplantation (allo-HCT), we descri

194 which is the main complication of allogeneic hematopoietic cell transplantation (allo-HCT).

195 sus-host disease (GVHD) following allogeneic hematopoietic cell transplantation (allo-HCT).

196 fe-threatening complication after allogeneic hematopoietic cell transplantation (allo-HCT).

197 of morbidity and mortality after allogeneic hematopoietic cell transplantation (allo-HCT).

198 ntensive chemotherapy followed by allogeneic hematopoietic cell transplantation (alloHCT) and single-

199 Allogeneic hematopoietic cell transplantation (alloHCT) benefits in

200 graft-vs-tumor effects following allogeneic hematopoietic cell transplantation (alloHCT), but retros

201 in at risk for relapse even after allogeneic hematopoietic cell transplantation (alloHCT).

202 ory DLBCL who were ineligible for autologous hematopoietic cell transplantation (auto-HCT) or who had

203 depletion regimen (HR, 0.25), and allogeneic hematopoietic cell transplantation (HCT) after CAR T-cel

204 tranded DNA (dsDNA) viruses after allogeneic hematopoietic cell transplantation (HCT) are limited by

205 Post hematopoietic cell transplantation (HCT) autoimmune cyto

206 Allogeneic hematopoietic cell transplantation (HCT) benefits childr

207 er insight into humoral viral immunity after hematopoietic cell transplantation (HCT) could have pote

208 ematologic malignancies and those undergoing hematopoietic cell transplantation (HCT) face a complex

209 ary immunodeficiencies undergoing allogeneic hematopoietic cell transplantation (HCT) for difficult-t

210 ite improvements, mortality after allogeneic hematopoietic cell transplantation (HCT) for nonmalignan

211 st disease (GVHD) is higher after allogeneic hematopoietic cell transplantation (HCT) from unrelated

212 Hematopoietic cell transplantation (HCT) has been consid

213 Hematopoietic cell transplantation (HCT) has now been sh

214 ltivariate Cox model for OS using allogeneic hematopoietic cell transplantation (HCT) in first comple

215 nonrelapse mortality (NRM) after allogeneic hematopoietic cell transplantation (HCT) in the pediatri

216 Hematopoietic cell transplantation (HCT) is curative for

217 rimary cytomegalovirus (CMV) infection after hematopoietic cell transplantation (HCT) is poorly under

218 Relapse after allogeneic hematopoietic cell transplantation (HCT) is the leading

219 gnificant morbidity and early mortality, and hematopoietic cell transplantation (HCT) is the only wid

220 Hematopoietic cell transplantation (HCT) is the primary

221 C) transfusion practices and their impact on hematopoietic cell transplantation (HCT) outcomes are po

222 psychological distress during their child's hematopoietic cell transplantation (HCT) process.

223 prophylaxis after matched-related allogeneic hematopoietic cell transplantation (HCT) recently showed

224 sing polymerase chain reaction in allogeneic hematopoietic cell transplantation (HCT) recipients who

225 eria are associated with adverse outcomes in hematopoietic cell transplantation (HCT) recipients.

226 (CMV) is the most common viral infection in hematopoietic cell transplantation (HCT) recipients.

227 ersus placebo in CMV-seropositive allogeneic hematopoietic cell transplantation (HCT) recipients.

228 Hematopoietic cell transplantation (HCT) remains the onl

229 am infection (BSI) on outcomes of allogeneic hematopoietic cell transplantation (HCT) utilizing the C

230 been effective in preventing acute GvHD post hematopoietic cell transplantation (HCT), its efficacy a

231 (GvHD) is a major complication of allogeneic hematopoietic cell transplantation (HCT), mediated prima

232 rent treatment options, including allogeneic hematopoietic cell transplantation (HCT), often fail to

233 In patients who undergo allogeneic hematopoietic cell transplantation (HCT), post-HCT clone

234 -6B) frequently reactivates after allogeneic hematopoietic cell transplantation (HCT).

235 d nonmyeloablative conditioning regimens for hematopoietic cell transplantation (HCT).

236 e (aGVHD) hinders the efficacy of allogeneic hematopoietic cell transplantation (HCT).

237 nked to poor outcomes in patients undergoing hematopoietic cell transplantation (HCT).

238 has had a marked impact on human allogeneic hematopoietic cell transplantation (HCT).

239 ll-recognized after myeloablative allogeneic hematopoietic cell transplantation (HCT).

240 Ss) are life-threatening complications after hematopoietic cell transplantation (HCT).

241 onditioning for HLA class I or II mismatched hematopoietic cell transplantation (HCT).

242 with symptomatic hemorrhagic cystitis after hematopoietic cell transplantation (HCT).

243 , 113 patients with ALL underwent allogeneic hematopoietic cell transplantation (HCT); frequency of S

244 major barrier to engraftment after in utero hematopoietic cell transplantation (IUHCT).

245 Strategies to enhance the safety of hematopoietic cell transplantation and to improve patien

246 Allogeneic hematopoietic cell transplantation at the time of second

247 Hematopoietic cell transplantation can correct hematolog

248 The success of allogeneic hematopoietic cell transplantation depends heavily on th

249 depletion of donor CD4+ T cells early after hematopoietic cell transplantation effectively prevents

250 e is a major cause of death after allogeneic hematopoietic cell transplantation for acute leukemias.

251 t event-free survival (EFS) after allogeneic hematopoietic cell transplantation for sickle cell disea

252 s in a cohort of 2531 patients who underwent hematopoietic cell transplantation from 2010 to 2015 aft

253 versus-host disease (aGVHD) after allogeneic hematopoietic cell transplantation have poor prognosis,

254 Allogeneic hematopoietic cell transplantation involves consideratio

255 Allogeneic hematopoietic cell transplantation is indicated for refr

256 re previously treated with either autologous hematopoietic cell transplantation or two or more prior

257 sociated with higher mortality in allogeneic hematopoietic cell transplantation recipients with LRTD.

258 t disease (GvHD) is a common complication of hematopoietic cell transplantation that negatively impac

259 (GVHD) is a major complication of allogeneic hematopoietic cell transplantation that resembles autoim

260 induced hematopoietic syndrome is allogeneic hematopoietic cell transplantation, a therapy unavailabl

261 analysis of a nonhematologic neoplasm, after hematopoietic cell transplantation, or as a result of ge

262 d improved survival in a model of allogeneic hematopoietic cell transplantation, providing the ration

263 national Histocompatibility Working Group in Hematopoietic Cell Transplantation.

264 s, with and without censoring for allogeneic hematopoietic cell transplantation.

265 herapy regimens if ineligible for autologous hematopoietic cell transplantation.

266 the most serious complication of allogeneic hematopoietic cell transplantation.

267 three additional courses of chemotherapy or hematopoietic cell transplantation.

268 of morbidity and mortality after allogeneic hematopoietic cell transplantation.

269 life-threatening complication of allogeneic hematopoietic cell transplantation.

270 reduce the risk of relapse after allogeneic hematopoietic cell transplantation.

271 lly validating this model in unrelated donor hematopoietic cell transplantation.

272 iders who care for patients after allogeneic hematopoietic cell transplantation.

273 inib use, but its cytomegalovirus risk after hematopoietic-cell transplantation (HCT) is not known.

274 and its complications in adult patients with hematopoietic cell transplants (HCT), cancer (hematologi

275 ociated complications in adult patients with hematopoietic cell transplants (HCT), cancer, human immu

276 In hematopoietic cell transplants, alloreactive T cells med

277 atment, these responder patients, as well as hematopoietic cells treated with FeCl(3) and Deferasirox

278 n-regulation of MHC-I on a small fraction of hematopoietic cells triggered missing-self reactivity.

279 crophages (TAMs) represent the most abundant hematopoietic cell type in the solid tumor microenvironm

280 -Class to analyze 32 datasets from different hematopoietic cell types from the Blueprint Epigenome pr

281 the regulatory landscape of differentiating hematopoietic cell types in mouse.

282 u.1 regulation from those described in other hematopoietic cell types such as T cells which down-regu

283 45(+) AGM cells revealed predominance of two hematopoietic cell types, mannose-receptor positive macr

284 c stem cell niche and are thought to protect hematopoietic cells under stress.

285 ound that constitutive MDR1 expression among hematopoietic cells was observed in cytolytic lymphocyte

286 RA in nonhematopoietic cells, but not in the hematopoietic cells, was required for the development of

287 n in thymic epithelial cells (TECs), but not hematopoietic cells, was sufficient for complete deletio

288 molecular characteristics of the developing hematopoietic cells, we lack a complete understanding of

289 transcriptomic and metabolomic profiling of hematopoietic cells, we reveal that EVI1 overexpression

290 era experiments showed that CD137L-deficient hematopoietic cells were able to confer T1D resistance.

291 Stromal, but not hematopoietic, cells were the essential source of Notch

292 ion mostly depends upon Notch3 expression in hematopoietic cells, which coincides with an enhanced pr

293 The Y chromosome is frequently lost in hematopoietic cells, which represents the most common so

294 Non-leukemic hematopoietic cells with DNMT3A(R882H) displayed focal m

295 tential (CHIP), the age-related expansion of hematopoietic cells with leukemogenic mutations without

296 t ZIKV infection was particularly evident in hematopoietic cells with microglia, the brain-resident m

297 NA in humans showed that clonal expansion of hematopoietic cells with somatic mutations in leukemogen

298 infected fibroblasts, endothelial cells, and hematopoietic cells, with some infected cells able to tr

299 ned by the continuous interactions of mobile hematopoietic cells within specialized microenvironments

300 Constitutive activation of beta-catenin in hematopoietic cells yielded lethal myeloid disease in a